<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04898387</url>
  </required_header>
  <id_info>
    <org_study_id>LT4030-301</org_study_id>
    <nct_id>NCT04898387</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Assessment of T4030 Eye Drops Versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients.</brief_title>
  <official_title>Efficacy and Safety Assessment of T4030 Eye Drops Versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires Thea</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoires Thea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the non-inferiority of T4030 unpreserved eye drops compared to Ganfort® UD in&#xD;
      terms of efficacy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efficacy Parameters IOP assessment in each eye&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>The 2 different treatment kits should be identical in external packaging in order to respect the masked evaluation for efficacy and safety.&#xD;
The identity of the IMP given to each patient will not be known by the masked investigator</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>IOP assessment</measure>
    <time_frame>Week 12</time_frame>
    <description>The primary efficacy endpoint is the change from Baseline (Day 1) to Week 12 in IOP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular Sign</measure>
    <time_frame>Week 6 Week 12</time_frame>
    <description>Ocular sign will be assessed through slit lamp examination at each visits</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Ocular Hypertension Glaucoma</condition>
  <arm_group>
    <arm_group_label>T4030 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ganfort Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Bimatoprost Timolol (T4030)</intervention_name>
    <description>Eye drop</description>
    <arm_group_label>T4030 Group</arm_group_label>
    <other_name>Bimatoprost Timolol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Bimatoprost Timolol (Ganfort)</intervention_name>
    <description>Eye drop</description>
    <arm_group_label>Ganfort Group</arm_group_label>
    <other_name>Bimatoprost Timolol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent signed and dated*&#xD;
&#xD;
          -  Patient aged ≥18 years old&#xD;
&#xD;
          -  Both eyes with a central corneal thickness assessment ≥500 µm and ≤600 μm a&#xD;
&#xD;
          -  Both eyes with diagnosed ocular hypertension or open angle glaucoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of narrow angle and/or angle closure glaucoma&#xD;
&#xD;
          -  Advanced stage of glaucoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CORENTIN LECAMUS</last_name>
    <role>Study Director</role>
    <affiliation>Laboratoires Thea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CORENTIN LECAMUS, Medical Director</last_name>
    <phone>0635156436</phone>
    <email>Corentin.lecamus@theapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical Center Vereya EOOD</name>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nataliya Ivanova, md</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>May 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Bimatoprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

